If you have been reading about fatty acid oxidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-29. Numbers and descriptions here follow the published literature rather than marketing material.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
=== Contraindications === A few contraindications should be taken into account for atomoxetine. The first one is hypersensitivity; patients known to be hypersensitive to atomoxetine or other constituents of the product should avoid using it. MAO inhibitors (MAOI) should also be taken into account for contraindications. Atomoxetine should not be taken within 2 weeks after discontinuing an MAOI or completely avoid taking MAOI. The same applies to treatment with an MAOI, that it should not be initiated within 2 weeks after discontinuing atomoxetine. Serious and sometimes fatal reactions may occur when atomoxetine and drugs that affect brain monoamine concentration are given concurrently or in close proximity. Examples of reactions are hyperthermia, inflexibility, myoclonus and altered mental states that include extreme agitation, possibly progressing to delirium and coma. Increased risk of mydriasis was associated with Strattera use in clinical trials. Therefore, the use of Strattera is not recommended in patients with narrow angle glaucoma. Patients with pheochromocytoma or a history of pheochromocytoma should not take Strattera because serious reactions (elevated blood pressure and tachyarrhythmia) have been reported in patients who received Strattera. Last but not least, patients with severe cardiac or vascular disorders should not be using Strattera. The only contraindication that is reported in the IMB Micromedex database is prior hypersensitivity to the active compound, reboxetine.
== Further reading == Jensen, Carsten (2012). Controversy and Consensus: Nuclear Beta Decay 1911–1934 (illustrated ed.). Springer. ISBN 9783034884440. Tomonaga, S.-I. (1997). The Story of Spin. University of Chicago Press.
== Treatment == Treatment is focused on reducing stroke episodes and damage from a distending artery. Four treatment modalities have been reported in the treatment of vertebral artery dissection. The two main treatments involve medication: anticoagulation (using heparin and warfarin) and antiplatelet drugs (usually aspirin). More rarely, thrombolysis (medication that dissolves blood clots) may be administered, and occasionally obstruction may be treated with angioplasty and stenting. No randomized controlled trials have been performed to compare the different treatment modalities. Surgery is only used in exceptional cases.
== External links == Sugimura T, Nagao M, Wakabayashi K (May 1996). "Carcinogenicity of food mutagens". Environmental Health Perspectives. 104 (Suppl 3): 429–33. doi:10.2307/3432798. JSTOR 3432798. PMC 1469643. PMID 8781358. Louis ED, Zheng W, Jiang W, Bogen KT, Keating GA (June 2007). "Quantification of the neurotoxic beta-carboline harmane in barbecued/grilled meat samples and correlation with level of doneness". Journal of Toxicology and Environmental Health, Part A. 70 (12): 1014–9. Bibcode:2007JTEHA..70.1014L. doi:10.1080/15287390601172015. PMC 4993204. PMID 17497412.
=== Campaign expenditures === According to First Amendment scholar Floyd Abrams, the act "was the first law barring unions and corporations from making independent expenditures in support of or [in] opposition to federal candidates".
Sources: en.wikipedia.org
== Clinical Significance == Many diseases such as Human African trypanosomiasis, Nagana disease in cattle, and Chagas disease are caused by kinetoplastid parasites. Such diseases infect an estimated 15 to 20 million people per year worldwide and kill 100000 to 150000 of those infected. Current treatments for these diseases were generally made almost 100 years ago and in that time many of the parasites have developed resistance, in addition, many of the original treatments are highly toxic. Targeting trypanothione synthase could be a novel way of preventing and curing these diseases through disruption of the parasites' metabolism. Scientists believe that the thiol metabolic pathway is an especially good target for anti-parasitic drug production as trypanothione based thiol redox is absent in humans and it is thought that thiol redox is key in the mechanisms some parasites have in order to obtain drug resistance .
The structure of TEV protease has been solved by X-ray crystallography. It is composed of two β-barrels and a flexible C-terminal tail and displays structural homology to the chymotrypsin superfamily of proteases (PA clan, C4 family by MEROPS classification). Although homologous to cellular serine proteases (such as trypsin, elastase, thrombin etc.), TEV protease uses a cysteine as its catalytic nucleophile (as do many other viral proteases). Covalent catalysis is performed with an Asp-His-Cys triad, split between the two barrels (Asp on β1 and His and Cys on β2). The substrate is held as a β-sheet, forming an antiparallel interaction with the cleft between the barrels and a parallel interaction with the C-terminal tail. The enzyme therefore forms a binding tunnel around the substrate and side chain interactions control specificity.
In the United States, all of the northern states had abolished slavery by 1804, with New Jersey being the last to act. Abolitionist pressure produced a series of small steps towards emancipation. After the Act Prohibiting Importation of Slaves went into effect on January 1, 1808, the importation of slaves into the United States was prohibited, but not the internal slave trade, nor involvement in the international slave trade externally. Legal slavery persisted outside the northern states, but abolitionists took an active role in opposing slavery by supporting the Underground Railroad, and violent clashes between anti-slavery and pro-slavery Americans occurred, including in Bleeding Kansas, a series of political and armed disputes in 1854–1858 as to whether Kansas would join the United States as a slave or free state. By 1860, the total number of slaves reached almost four million, and the American Civil War, beginning in 1861, led to the end of slavery in the United States. Slaves in areas controlled by the Confederacy were legally emancipated in 1863, when Lincoln issued the Emancipation Proclamation, and slavery was banned nationwide, except as punishment for a crime, in 1865, with the ratification of the 13th Amendment to the U.S. Constitution. Many of the freed slaves became sharecroppers and indentured servants.
The Ocean Race is a yacht race around the world, held every three or four years since 1973. Originally named the Whitbread Round the World Race after its initiating sponsor, British brewing company Whitbread, in 2001 it became the Volvo Ocean Race after Swedish automobile manufacturer Volvo took up the sponsorship, and in 2019 it was renamed The Ocean Race. Each of the entries has a sailing crew who race day and night for more than 20 days at a time on some of the legs. Since the 2008–2009 race there has also been a dedicated media crew member called the On Board Reporter (OBR), who does not contribute to the sailing of the boat, but is responsible for sending images and video to race headquarters via satellite from the middle of the ocean. In the 2017–2018 race, the number of crew ranged between 7 and 10 (plus the OBR) depending on the gender ratio, with the rules providing an incentive to having women sailors on board. To minimize weight, crews overwhelmingly rely on freeze-dried fare for sustenance. Crews are also subjected to temperature variations from −5 to +40 degrees Celsius and will often take only one change of clothes.
=== Reaction and responses to doubt === Evans has said he has received online abuse from supporters of Letby who question the safety of her convictions. He argued that some people struggle to accept that a perpetrator could be "a young, white, English nurse from a respectable background", citing the examples of Harold Shipman and Jimmy Savile for how an outward appearance of being "normal" had aided in hiding crimes. A barrister representing the infants' families described doubts about the convictions as "conspiracies, some of which are grossly offensive and distressing for the families of her victims". The families' legal representatives argued that the Thirlwall Inquiry should be publicly livestreamed to counter misinformation. The inquiry rejected the application, concluding that livestreaming was unnecessary. BBC special correspondent Judith Moritz, one of four reporters permitted in the courtroom, told The Sunday Times that public debate about the case often overlooked the jury's experience of observing Letby. Moritz said Letby appeared tearful when discussing herself, her job loss and the testifying in court by a married doctor with whom she had exchanged numerous Facebook messages, but not "particularly" affected when the infants' deaths were discussed. By contrast, Guardian correspondent Josh Halliday reported that Letby did become tearful when discussing the infants' deaths, including during police interviews. Moritz also said that Letby contradicted herself and attempted to "out-lawyer" the prosecutor.
Sources: en.wikipedia.org
(WINNER) The contestant won the whole competition. (WIN) The contestant won "The Killer" (Main Heat challenge). (HIGH) The contestant had one of the best dishes for that week. (IN) The contestant performed well enough to move on to the next week. (LOW) The contestant competed in a Bake Off, but was not eliminated. (LOW) The contestant had one of the bottom dishes for that week, but was not eliminated. (OUT) The contestant competed in a Bake Off and was eliminated for the worst dish. (OUT) The contestant was eliminated for worst dish. ‡The contestant won "The Thriller" (Preheat challenge)
By the mid-2020s, Zipline had become an example of a Silicon Valley startup whose most visible commercial activity occurred abroad rather than domestically, with most of its business based on government contracts for transporting medical supplies to remote or hard-to-reach areas in multiple African countries. In April 2024, Zipline completed its millionth commercial delivery, having flown more than 70 million autonomous commercial miles. In January 2026, Zipline completed its two millionth commercial delivery, with over 120 million autonomous miles flown.
The sulfur dioxide is used for the production of sulfuric acid, which is necessary for the leaching process. If deposits of zinc carbonate, zinc silicate, or zinc-spinel (like the Skorpion Deposit in Namibia) are used for zinc production, the roasting can be omitted. For further processing two basic methods are used: pyrometallurgy or electrowinning. Pyrometallurgy reduces zinc oxide with carbon or carbon monoxide at 950 °C (1,740 °F) into the metal, which is distilled as zinc vapor to separate it from other metals, which are not volatile at those temperatures. The zinc vapor is collected in a condenser. The equations below describe this process:
Writing for The Guardian, Seumas Milne stated the result of the post–Cold War narrative that Stalin and Hitler were twin evils, therefore communism is as monstrous as Nazism, "has been to relativise the unique crimes of Nazism, bury those of colonialism and feed the idea that any attempt at radical social change will always lead to suffering, killing and failure." Other leftists, including some Marxist–Leninists, apply self-criticism, and have at times criticised Marxist–Leninist praxis and some actions by Marxist–Leninist governments, while acknowledging its advancements, emancipatory acts such as their support of labour rights, women's rights, anti-imperialism, democratic efforts, egalitarian achievements, modernisation, and the creation of mass social programs for education, health, housing, and jobs as well as the increase of living standards.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.